Gilead market cap up $35 Billion since purchase of VRUS for $11 Billion
Read that Seeking Alpha article very closely.
What was seen as an extremely high price of $11 Billion to acquire Pharmasset when Gilead had a $32 Billion Market Cap is now seen as a brilliant move by Gilead. They are being rewarded handsomely by the Street with a nearly $70 Billion market cap 16 months after the deal.
Have a feeling the monumental size of the diabetes opportunity will force some hands here (Lilly, Merck, Sanfoli) to either put up or get shut out of what may be a $15 to $25 Billion global annual revenue opportunity within 3 to 5 years.
MNKD must be looking really attractive to these big players.
Wonder how much data MNKD has shared with potential suitors ( as did VRUS before a bidding war broke out for them prior to Gilead winning).
Gilead Sciences Inc. GILD agreed to acquire drug developer Pharmasset Inc. for nearly $11 billion, placing a big bet on the market for new treatments for hepatitis C infections.
The offer represents a nearly 89% premium to Pharmasset's closing price Friday and an impressive return for a stock that traded below $10 as recently as January 2010. Pharmasset shares soared 85% to $134.14 in Monday afternoon trading on the Nasdaq Stock Market.
From Wall Street Journal Article November 2011
Note: Gilead Market Cap was $29.9 Billion at the time it acquired Pharmasset for $11 Billion. Gilead spent 37% of their $29.9 Billion Market Cap to acquire the potential Pharmasset Hep C drug - PRE FDA Approval.
Lilly, Merck and Sanofi are the rumored potential interested parties in MNKD. The average Market Cap of the three is $105 Billion.
They most certainly could make an acquisition in the $10 to $20 Billion Range.
Especially if it will help them double their market cap like the Gilead acquisition of Pharmasset.
With nearly 30% of the public float traded over the last 2 days - it would seem there may indeed be ample interest in acquiring or partnering with MNKD by the likes of Lilly, Sanofi, Merck or possibly a completely unknown potential partner.